Danese M D, Ladenson P W, Meinert C L, Powe N R
Department of Epidemiology, The Johns Hopkins University School of Hygiene and Public Health, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2223, USA.
J Clin Endocrinol Metab. 2000 Sep;85(9):2993-3001. doi: 10.1210/jcem.85.9.6841.
The objective of our study was to estimate the expected change in serum lipoprotein concentrations after treatment with T4 in patients with mild thyroid failure (i.e. subclinical hypothyroidism). Our data sources included MEDLINE, between January 1966 and May 1999, and review of references from relevant articles. There were 1,786 published studies identified, 461 abstracts reviewed, 74 articles retrieved, 24 articles evaluated against predetermined entry criteria, and 13 studies systematically reviewed and abstracted. All studies reported serum total cholesterol concentration changes during T4 treatment, 12 reported triglyceride changes, 10 reported high-density lipoprotein (HDL) cholesterol changes, and 9 reported low-density lipoprotein (LDL) cholesterol changes. There were 247 patients in 13 studies. The mean decrease in the serum total cholesterol concentration was -0.20 mmol/L (-7.9 mg/ dL), with a 95% confidence interval of -0.09 to -0.34. The decline in serum total cholesterol was directly proportional to its baseline concentration. Studies enrolling hypothyroid participants receiving suboptimal T4 doses reported significantly larger decreases in serum total cholesterol after thyroid-stimulating hormone normalization than studies enrolling previously untreated individuals with mild thyroid failure [-0.44 mmol/L (-17 mg/dL) vs. -0.14 mmol/L (-5.6 mg/dL), P = 0.05]. The change in serum LDL cholesterol concentration was -0.26 mmol/L (-10 mg/dL), with a 95% confidence interval of -0.12 to -0.41. Serum HDL and triglyceride concentrations showed no change. These results, although based on fewer than 250 patients, suggest that T4 therapy in individuals with mild thyroid failure lowers mean serum total and LDL cholesterol concentrations. The reduction in serum total cholesterol may be larger in individuals with higher pretreatment cholesterol levels and in hypothyroid individuals taking suboptimal T4 doses. There do not seem to be significant effects of T4 on serum HDL or triglyceride concentrations.
我们研究的目的是评估轻度甲状腺功能减退(即亚临床甲状腺功能减退症)患者接受T4治疗后血清脂蛋白浓度的预期变化。我们的数据来源包括1966年1月至1999年5月期间的MEDLINE以及相关文章参考文献的回顾。共识别出1786项已发表研究,查阅了461篇摘要,检索到74篇文章,根据预定入选标准评估了24篇文章,系统回顾并提取了13项研究。所有研究均报告了T4治疗期间血清总胆固醇浓度的变化,12项报告了甘油三酯变化,10项报告了高密度脂蛋白(HDL)胆固醇变化,9项报告了低密度脂蛋白(LDL)胆固醇变化。13项研究中有247名患者。血清总胆固醇浓度的平均下降为-0.20 mmol/L(-7.9 mg/dL),95%置信区间为-0.09至-0.34。血清总胆固醇的下降与其基线浓度成正比。与纳入轻度甲状腺功能减退且未经治疗个体的研究相比,纳入接受次优T4剂量的甲状腺功能减退参与者的研究在促甲状腺激素正常化后血清总胆固醇下降幅度显著更大[-0.44 mmol/L(-17 mg/dL)对-0.14 mmol/L(-5.6 mg/dL),P = 0.05]。血清LDL胆固醇浓度变化为-0.26 mmol/L(-10 mg/dL),95%置信区间为-0.12至-0.41。血清HDL和甘油三酯浓度无变化。这些结果虽然基于不到250名患者,但表明轻度甲状腺功能减退患者接受T4治疗可降低血清总胆固醇和LDL胆固醇的平均浓度。血清总胆固醇的降低在治疗前胆固醇水平较高的个体以及服用次优T4剂量的甲状腺功能减退个体中可能更大。T4对血清HDL或甘油三酯浓度似乎没有显著影响。